Findings

What do systematic reviews say?

3 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 2 · 33.3%High 0 · 0%

PDEI + 5‐ARI vs 5‐ARI alone

IPSS‐total score

2 findings from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 695 participants
Moderate
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 695 participants
Moderate

PDEI + 5‐ARI vs 5‐ARI alone

BPHII score

The review found no eligible studies for this question.

2 findings from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

PDEI + 5‐ARI vs 5‐ARI alone

Adverse events

The review found no eligible studies for this question.

2 findings from 1 review

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
RR 1.07 [0.84, 1.36]
1 study · 695 participants
Low